Russia faces shortage of anticancer drug Ixempra
Russia has faced a shortage of another important anticancer drug - Ixempra (ixabepilone), which is designed for the treatment of breast cancer, reports The Pharma Letter’s local correspondent.
Over the past two years, the drug's right holder - the American subsidiary of the Russian drugmaker R-Pharm - has launched only one series of the drug into the Russian market. The company explains that due to a change in the distributor of the active ingredient, the drug has become more expensive. In this regard, R-Pharm hopes for an increase of the maximum price of the drug in order to resume supplies.
R-Pharm US acquired rights to the drug from US pharma major Bristol-Myers Squibb (NYSE: BMY) in 2015. There are no analogues of Ixempra in Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze